Compare · AGL vs MRAI
AGL vs MRAI
Side-by-side comparison of agilon health inc. (AGL) and Marpai Inc. (MRAI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AGL and MRAI operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- AGL is the larger of the two at $1.59B, about 36.5x MRAI ($43.5M).
- AGL has been more active in the news (10 items in the past 4 weeks vs 9 for MRAI).
- AGL has more recent analyst coverage (25 ratings vs 0 for MRAI).
- Company
- agilon health inc.
- Marpai Inc.
- Price
- $98.20+2.95%
- $0.92-55.67%
- Market cap
- $1.59B
- $43.5M
- 1M return
- +81.87%
- -
- 1Y return
- +71.89%
- -
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- 2021
- News (4w)
- 10
- 9
- Recent ratings
- 25
- 0
agilon health inc.
agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. The company was founded in 2016 and is based in Long Beach, California.
Marpai Inc.
Marpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market. It also offers ancillary services, such as care management, case management, actuarial services, health savings account administration, and cost containment services. The company was incorporated in 2021 and is based in Tampa, Florida.
Latest AGL
- Chief Legal Officer Zamore Denise covered exercise/tax liability with 485 shares, decreasing direct ownership by 0.73% to 66,112 units (SEC Form 4) (tax liability)
- Director Wulf John William was granted 2,133 shares, increasing direct ownership by 15% to 16,765 units (SEC Form 4)
- Director Williams Ronald A was granted 2,133 shares, increasing direct ownership by 1% to 149,141 units (SEC Form 4)
- Director Mcloughlin Karen was granted 2,133 shares, increasing direct ownership by 35% to 8,207 units (SEC Form 4)
- Director Mckenzie Diana was granted 2,133 shares, increasing direct ownership by 39% to 7,633 units (SEC Form 4)
- Director Mansukani Sharad was granted 2,133 shares, increasing direct ownership by 4% to 56,242 units (SEC Form 4)
- Director Battaglia Silvana was granted 2,133 shares, increasing direct ownership by 37% to 7,926 units (SEC Form 4)
- agilon health inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Chief Accounting Officer Gertsch Timothy covered exercise/tax liability with 8 shares, decreasing direct ownership by 0.06% to 14,169 units (SEC Form 4) (for withholding tax)
- agilon health upgraded by Barclays with a new price target
Latest MRAI
- Director Eitan Yaron returned 50,000 shares to the company and was granted 175,000 shares, decreasing direct ownership by 4% to 1,224,073 units (SEC Form 4)
- Chief Financial Officer Johnson Steve Andrew was granted 125,000 shares and bought $682 worth of shares (1,100 units at $0.62), increasing direct ownership by 14% to 1,024,192 units (SEC Form 4)
- Director Shiv Sagiv returned 50,000 shares to the company and was granted 125,000 shares, decreasing direct ownership by 8% to 613,667 units (SEC Form 4)
- Director Pons Robert M returned 50,000 shares to the company and was granted 100,000 shares, decreasing direct ownership by 9% to 484,200 units (SEC Form 4)
- Director Calabrese Jennifer Rosario returned 50,000 shares to the company and was granted 100,000 shares, decreasing direct ownership by 18% to 225,000 units (SEC Form 4)
- Chief Executive Officer Lamendola Damien was granted 300,000 shares, increasing direct ownership by 22% to 1,650,000 units (SEC Form 4)
- Director Diclaudio Colleen was granted 125,000 shares, increasing direct ownership by 88% to 267,500 units (SEC Form 4)
- Marpai Inc. Announces Unprecedented Growth with 192,000 New Estimated Member Lives Across TPA and MarpaiRx PBM Platforms; Expects to Achieve Positive Cash Flow and EBITDA Beginning August 2026
- Director Eitan Yaron bought $2,700 worth of shares (10,000 units at $0.27), increasing direct ownership by 0.92% to 1,099,073 units (SEC Form 4)
- SEC Form 10-Q filed by Marpai Inc.